Home > Neurology > MS Virtual 2020 > Biomarkers > Serum glial fibrillary acidic protein predicts relapses in NMOSD

Serum glial fibrillary acidic protein predicts relapses in NMOSD


Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22
Conference
MS Virtual 2020
The astrocyte-specific marker glial fibrillary acidic protein (GFAP), measured in serum, can predict relapses in neuromyelitis optica spectrum disorders (NMOSD) during remission. Two other biomarkers, S100B and neurofilament light chain (NfL) failed to do so [1]. In acute phases of NMOSD, the astrocyte-specific biomarkers GFAP and S100B are elevated in cerebrospinal fluid (CSF) and serum or plasma, as is the neuron-specific biomarker NfL. GFAP is already used to set appropriate treatment regimens and monitoring response. In a new study, the prognostic potential of these 3 biomarkers for future relapses in NMOSD with aquaporin-4-IgG was evaluated. Median baseline biomarker values were determined from 47 serum samples from 18 patients in remission. Cut-off levels were established for “high” and “low” GFAP (141.6 pg/mL), S100B (8.6 pg/mL), and NfL (33.9 pg/mL). When a patient relapsed, another serum sample was taken and analysed. In total, 25 post-relapse sam...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on